ライフサイエンスコーパス: oral treatment

1 eek group (difference 3.7% [-4.8 to 12.2] vs oral treatment).

2 ion of new, or the augmentation of existing, oral treatment.

3 avenous steroids, whereas 6220 (8%) received oral treatment.

4 is and adjuvant-induced arthritis, following oral treatment.

5 days, with an average of 4.0 +/- 3.0 days of oral treatment.

6 ting further development of this once daily, oral treatment.

7 for the LA regimen, compared with the daily oral treatment.

8 norrhoeae, for which there is no recommended oral treatment.

9 travenous treatment and to the epithelium in oral treatment.

10 fected mice at 40 and/or 60 mg/kg/10 days of oral treatment.

11 adermally, and when compared to conventional oral treatment.

12 et psychosocial issues associated with daily oral treatment.

13 ration route that has driven the need for an oral treatment.

14 intravenous treatment and 2205 (6%) received oral treatment.

15 y (38 artesunate and 49 quinine) followed by oral treatments.

16 confidence interval], 1.63 [1.55-1.72]), on oral treatment (1.23 [1.15-1.31]), and on diet alone (1.

17 ntained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week

18 ptoms and diagnosis, 3) health behaviors, 4) oral treatments, 5) oral prevention, and 6) patient perc

19 cted a randomized trial of directly observed oral treatment administered monthly to reduce vaginal in

20 icates that molecular modifications aimed at oral treatments against food allergy may or may not corr

21 pal injection of Abeta peptide in rats after oral treatment, altogether making 14qR (WLB-87848) an in

22 up (difference 2.8% [95% CI -5.8 to 11.5] vs oral treatment), and 109 (95%) of 115 patients in the 8-

23 r future trial design and studies of chronic oral treatment are discussed.

24 Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxys

25 Recovery of hearing on oral treatment at 2 months by intention-to-treat analysi

26 Lactational and oral treatment by gavage with TCS leads to the activatio

27 Oral treatments can be effective but may cause adverse e

28 prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dyna

29 of 513]), opioids (21% [106 of 513]), other oral treatments, (eg, methotrexate, cyclosporine, tacrol

30 Miltefosine, the only oral treatment, failed to achieve adequate efficacy, par

31 Subjects were randomly assigned to receive oral treatment for 3 years with risedronate (2.5 or 5 mg

32 y and increased permeability were induced by oral treatment for 4 days with dextran sulphate sodium (

33 Both oral treatment for 4 weeks and a single intravenous metf

34 The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899

35 Mitapivat could be a new oral treatment for adults with NTD alpha-thalassaemia or

36 OC000459 shows promise as a novel oral treatment for asthma and related disorders.

37 ed therapeutic in clinical development as an oral treatment for autoimmune diseases.

38 potential for use as a once- or twice-daily oral treatment for cancer.

39 Avatrombopag is an effective oral treatment for children and adolescents with ITP for

40 An effective, safe, and oral treatment for CL is required.

41 tential for a safe and effective nonabsorbed oral treatment for diabetes and support the concept of e

42 generation kinetin derivatives to develop an oral treatment for FD that can efficiently pass the bloo

43 of this novel class of small molecules as an oral treatment for FD.

44 rect-acting antiviral (DAA) therapy-curative oral treatment for HCV infection.

45 safety of a strategy of rapid uptitration of oral treatment for heart failure (HF) and close follow-u

46 ients at baseline, week 1, and week 2 of all-oral treatment for hepatitis C virus (HCV) infection.

47 tine after oral administration as a possible oral treatment for inflammatory bowel disease (IBD).

48 as a reasonable effectiveness as last-resort oral treatment for lower UTI and stepdown treatment for

49 od has recently been introduced as the first oral treatment for multiple sclerosis.

50 An oral treatment for neovascular age-related macular degen

51 inhibitor of glucosyltransferase, as a novel oral treatment for non-neuronopathic Gaucher's disease.

52 romising agent to be further developed as an oral treatment for OIC.

53 ntial of zuranolone as a novel, rapid-acting oral treatment for PPD.

54 FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis

55 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosi

56 inase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.

57 an effective and well tolerated non-hormonal oral treatment for vasomotor symptoms in women taking or

58 ailed by two to four classes of conventional oral treatments for migraine prevention were randomly as

59 controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.

60 failure (two in the 8-week group; one in the oral treatment group).

61 f the 4-week and 8-week groups and 56 to the oral treatment group).

62 t 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4

63 roups) and seven (13%) of 56 patients in the oral treatment group; none were drug related.

64 roin addicts who were receiving conventional oral treatment (>or=6 months), but continued to inject s

65 d over 5% body weight reduction after 14-day oral treatment in diet-induced obese (DIO) mice.

66 s not superior to a psychiatrist's choice of oral treatment in patients with schizophrenia and schizo

67 less nephrotoxic than tacrolimus upon 3-week oral treatment in rats.

68 P; a ligand to engage and activate dectin-1, oral treatment in vivo) significantly decreased tumor we

69 cular and topical therapies were superior to oral treatments in reducing pain.

70 Oral treatments include traditional agents such as metho

71 The availability of these various oral treatments is hoped to improve regimens that, if us

72 The low dose daily oral treatment may help patients with intermittent maint

73 groups (n=7 each) for 3 weeks received daily oral treatment of 1 of these regimens: (1) control, vehi

74 ythrocytic Plasmodium yoelii infection after oral treatment of 25 mg/kg x 4 days or 80 mg/kg x 1 day

75 We tested oral treatment of ADS024 in multiple models of neuroinfl

76 Oral treatment of APPswe/PS1dE9 (APP/PS1) mice, a famili

77 Remarkably, a brief 9 d oral treatment of APPswe/PS1Deltae9 mice with pioglitazo

78 Oral treatment of C. difficile-infected mice with the PP

79 We also show that oral treatment of caged bees with pilocarpine, a muscari

80 Most importantly, oral treatment of chrysin to transgenic mice that expres

81 We performed a preventative oral treatment of Col4a1 mutant mice with the chemical c

82 Oral treatment of diabetic rodents with ebselen, a GPx m

83 afe and effective chemotherapeutic agent for oral treatment of drug-resistant human lymphomas.

84 more potent, less neurotoxic agents for the oral treatment of drug-resistant malaria, we utilized co

85 ed web-based service, to receive twice-daily oral treatment of either amiloride 5 mg, fluoxetine 20 m

86 Oral treatment of Hpdl(-/-) pups with 4-HMA or 4-HB enab

87 Oral treatment of infected BALB/c mice with imipramine i

88 l provide data that challenge the entrenched oral treatment of iron deficiency anemia.

89 The results from the POET (Partial Oral Treatment of left-sided Endocarditis) trial were pu

90 Oral treatment of MIA offspring with the human commensal

91 Syn aggregation in biochemical assays, while oral treatment of mice with a gut-restricted amyloid inh

92 Prolonged oral treatment of mice with antifungal drugs resulted in

93 rity, control of cardiac rhythm, and routine oral treatment of multiple sclerosis.

94 Oral treatment of neonatal lambs with JNJ-53718678, or w

95 e beta hemoglobinopathies and useful for the oral treatment of other anemias.

96 Moreover, oral treatment of P. falciparum episodes with parasitemi

97 premilast and crisaborole, are indicated for oral treatment of psoriasis and topical treatment of ato

98 romising alternative for the intravenous and oral treatment of pulmonary arterial hypertension (PAH).

99 Two months after oral treatment of rats with 4-methylumbelliferone (4-MU)

100 Oral treatment of rats with increased IOP with the CaN i

101 omising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly othe

102 Oral treatment of SARS-CoV-2-infected BALB/c mice with 1

103 Long-term oral treatment of SFD-SP rats with a selective p38 MAPK

104 and in vivo for their potential uses in the oral treatment of sickle cell disease symptoms.

105 nt model of gestational hypoxia that in vivo oral treatment of the mitochondria-targeted antioxidant

106 uppress GVHD while sparing the GVL, based on oral treatment of transplant donors with recipient Ags,

107 Not all practice guidelines on oral treatment of type 2 diabetes were consistent with a

108 pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the

109 class of antifungals and the only available oral treatment option for candidaemia.

110 a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-posit

111 Duvelisib may provide a new oral treatment option for this patient population of whi

112 ith no new safety concerns, offering a novel oral treatment option for uncomplicated urogenital gonor

113 ential role for zoliflodacin as an effective oral treatment option for uncomplicated urogenital gonor

114 ombosis a less burdensome and less expensive oral treatment option instead of a more expensive subcut

115 ueous solubility, limit their suitability as oral treatment option.

116 Oral treatment options for disease-modifying therapy in

117 ctively, but antimicrobial resistance limits oral treatment options for gonorrhea and M genitalium.

118 erculosis, offering safer and more effective oral treatment options.

119 ively affect patients' quality of life, with oral treatment preferable to most patients with cancer.

120 eated according to a standardized escalating oral treatment protocol (ibuprofen, metamizole, opioids)

121 Second-line oral treatments recommended include an opioid-antagonist

122 ledge, this is the first demonstration of an oral treatment reducing both LID and OFF time in patient

123 This oral treatment regimen also induced indefinite prolongat

124 We sought to develop a new and effective oral treatment regimen specific to children of different

125 To expedite the development of new oral treatment regimens for visceral leishmaniasis (VL),

126 ts with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter

127 of LCA at a much lower dosage (compared with oral treatment) showed a comparable antipsoriatic effect

128 This oral treatment strategy preserved QOL in treated patient

129 Because some oral treatments, such as cladribine, have long-lasting e

130 rp provides a promising safe and efficacious oral treatment that mechanistically differs from current

131 New oral treatments that target myeloma cells or bone marrow

132 ble adjustment, including the propensity for oral treatment, the risk of treatment failure among pati

133 nt need for safe, short-course, and low-cost oral treatments to combat this neglected disease.

134 r, particularly for patients who have failed oral treatment trials.

135 strategies, and the median time to starting oral treatment was 3 days (interquartile range, 0 to 4)

136 In the VPA-exposed rats maternal oral treatment was continued throughout pregnancy.

137 Definitive oral treatment was given at 36 h.

138 Once-daily oral treatment was highly efficacious at 5 milligrams pe

139 se in the placebo group (51 percent) in whom oral treatment was judged to have failed.

140 The ART-LUM oral treatment was used as a positive control.

141 fected sleep-wake architecture in rats after oral treatment, which we have previously shown to be ind

142 ment has evolved with the development of all-oral treatments, which are now given for 4-6 months for

143 Oral treatment with 1 mg of insulin twice per week for 2

144 ndomly assigned (2:1) to receive twice-daily oral treatment with 125 mg apilimod dimesylate capsules

145 Oral treatment with 2% sodium chloride (NaCl) for 7 days

146 The effects of oral treatment with 2'-fucosyllactose and 6'-sialyllacto

147 Daily oral treatment with 2'-fucosyllactose or 6'-sialyllactos

148 dine (EIDD-2749), and showed that once-daily oral treatment with 3 mg/kg of drug, initiated after the

149 Oral treatment with 40 mg pyridoxin hydrochloride for 28

150 ts were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus

151 The oral treatment with 7 (8 mg/kg/d) in a mouse model of IB

152 Oral treatment with a broad spectrum antibiotic modifies

153 Oral treatment with a combination of NAM and PN accelera

154 ey rat model of PNS-CNS injury, we show that oral treatment with a novel drug like RARbeta agonist, C

155 OPCs and we describe for the first time how oral treatment with a RARbeta agonist (C286, currently b

156 xenotransplanted into immunodeficient mice, oral treatment with a repurposed PAPD5 inhibitor, the di

157 to WT, we assess the impact of two-months of oral treatment with a silent allosteric modulator of mGl

158 r TLR2(-/-) mice demonstrate the ability for oral treatment with a TLR2 agonist to confer antiapoptot

159 is study was undertaken to determine whether oral treatment with a water-soluble N-hydroxy-2,2,6,6-te

160 Daily oral treatment with ABT-199 significantly increased surv

161 ts of intestinal short-chain fatty acids and oral treatment with acetate disclosed that resistance to

162 Oral treatment with acetate reverses social deficits and

163 Once-daily oral treatment with aliskiren lowers blood pressure effe

164 Thirty-nine patients received oral treatment with apatinib, and hepatic artery infusio

165 bladder muscle damage caused by BDL, whereas oral treatment with CDCA worsens the defective muscle co

166 Following oral treatment with CE, expression of the mast cell prot

167 le sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3.

168 In vivo oral treatment with compound 2 resulted in significant g

169 Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i

170 Among patients with notalgia paresthetica, oral treatment with difelikefalin resulted in modestly g

171 We used an oral treatment with dimethyl fumarate and the HCAR2 endo

172 onths) complete remission of the lymphoma by oral treatment with doxycycline monohydrate, 200 mg per

173 Oral treatment with either amoxicillin, 500 mg three tim

174 Oral treatment with either of these microbes reduces col

175 Moreover, oral treatment with either resveratrol or aspirin, the p

176 It can be concluded that a single dose, oral treatment with eltoprazine has beneficial antidyski

177 Although oral treatment with enalapril did not reduce focal trace

178 Natural gut microbiota were modified by oral treatment with enrofloxacin prior to sensitization

179 Oral treatment with enrofloxacin suppresses CS and produ

180 Two months after oral treatment with eplerenone, the subretinal fluid inc

181 t study we investigated the effectiveness of oral treatment with ethinyl estradiol (EE) on EAE and th

182 teral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the

183 Oral treatment with GS-441524, the parent nucleoside of

184 Oral treatment with HRO761 resulted in dose-dependent in

185 Oral treatment with increasing doses of rifampicin resul

186 Oral treatment with INH2BP (0.5 g/kg, daily), starting a

187 Here we report that oral treatment with insulin prevents virus-induced insul

188 ed in Zucker (fa/fa) rats following a 14-day oral treatment with INT131.

189 e METEORA-II trial compared a metronomic all-oral treatment with intravenous (IV) chemotherapy.

190 Oral treatment with Jun12682 improved survival and reduc

191 In a mouse model of SARS-CoV-2 infection, oral treatment with Jun13296 significantly improves surv

192 Oral treatment with L-arginine improves endothelial dysf

193 lock size four) in a 2:1 ratio to once-daily oral treatment with linagliptin 5 mg or matching placebo

194 Oral treatment with lithium preferentially inhibited the

195 Here we report that oral treatment with LTA-deficient NCK2025 normalizes inn

196 Oral treatment with minocycline, an inhibitor of microgl

197 rally challenged with C hominis oocysts, and oral treatment with MMV665917 was commenced 3 days after

198 In T2D rats, oral treatment with molidustat rescued the cardiac metab

199 s in BALB/c nude mice was inhibited by daily oral treatment with nilotinib.

200 mouse models of SLE (NZB/W F1 and MRL/lpr), oral treatment with NIM-1324 protected against weight lo

201 Oral treatment with NX-13 alleviates disease severity, c

202 ive voice and web response system to receive oral treatment with one of three doses of islatravir (0.

203 a proprietary computer-generated sequence to oral treatment with opicapone (5 mg, 25 mg, or 50 mg onc

204 We demonstrate that oral treatment with P. histicola mimics treatment with T

205 eactions and challenge outcome and prolonged oral treatment with penicillin in the diagnostic evaluat

206 ENDA program were supplemented with a 7-day oral treatment with penicillin.

207 Single oral treatment with placebo or eltoprazine, at 2.5, 5 an

208 Finally, oral treatment with prenol reduced fever, decreased lung

209 Oral treatment with probiotic bacteria has been shown to

210 anling Min mice were administered 6 weeks of oral treatment with R-FB using 2.5-25 mg/kg of R-FB once

211 Oral treatment with RVX208 reversed vascular remodeling

212 ndomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 2

213 We show that oral treatment with sterol-based LXR agonists in mice si

214 were randomly assigned to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg d

215 Concurrent oral treatment with the antioxidant CPI-1189 prevented a

216 and gsk3(WT) mice, before and after 1 wk of oral treatment with the beta-blocker propranolol.

217 Oral treatment with the beta3-AR-agonist mirabegron for

218 Maternal in vivo oral treatment with the mitochondria-targeted antioxidan

219 Oral treatment with the NOS substrate L-arginine at 5 g/

220 Oral treatment with the pyrazolopyridine KDU731 results

221 We show that oral treatment with the therapeutic agent diacetyl-bis(4

222 In conclusion, oral treatment with UDCA prevents gallbladder muscle dam

223 At 3 months after irradiation rats received oral treatment with vehicle, PTX, or PTX in combination

224 Daily oral treatments with OSU-A9 at 25 or 50 mg/kg for 56 day

225 Daily oral treatments with OSU-HDAC42 and SAHA, both at 25 mg/

226 Oral treatments with second-generation tetracyclines imp

227 acute (intravenous) and long-term (6 months, oral) treatment with carvedilol versus placebo in 151 co